Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Albelda

Showing results (71-80 of 197) with videos related to

Pageof 20
Sort By:
Oncoimmunology|February 6, 2018
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccinesEdmund K Moon, Liang-Chuan S Wang, Kheng Bekdache, et al.
Cancer Research|November 25, 2003
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapyPeter DeLong, Tomoyuki Tanaka, Robb Kruklitis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 9, 2008
B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor modelsSamuel Kim, Zvi G Fridlender, Robert Dunn, et al.
Blood|September 8, 2005
Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculatureBi-Sen Ding, Claudia Gottstein, Andrea Grunow, et al.
Cancer Research|September 14, 2011
Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptorAlain C Borczuk, Marieta Sole, Ping Lu, et al.
Neoplasia (New York, N.Y.)|May 12, 2012
Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgeryBrendan F Judy, Louis A Aliperti, Jarrod D Predina, et al.
Cancer Research|July 20, 2007
The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytesAfrica Wallace, David F LaRosa, Veena Kapoor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive TransferEdmund K Moon, Raghuveer Ranganathan, Evgeniy Eruslanov, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 26, 2024
Red blood cells function as reservoirs of tumor DNAJeffrey C Thompson, Sue Li, Joshua S Jose, et al.
Blood|March 22, 2003
PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosisCunji Gao, Weiyong Sun, Melpo Christofidou-Solomidou, et al.
Pageof 20

Showing results (71-80 of 197) with videos related to

Sort By:
Pageof 20
Oncoimmunology|February 6, 2018
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccinesEdmund K Moon, Liang-Chuan S Wang, Kheng Bekdache, et al.
Cancer Research|November 25, 2003
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapyPeter DeLong, Tomoyuki Tanaka, Robb Kruklitis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 9, 2008
B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor modelsSamuel Kim, Zvi G Fridlender, Robert Dunn, et al.
Blood|September 8, 2005
Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculatureBi-Sen Ding, Claudia Gottstein, Andrea Grunow, et al.
Cancer Research|September 14, 2011
Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptorAlain C Borczuk, Marieta Sole, Ping Lu, et al.
Neoplasia (New York, N.Y.)|May 12, 2012
Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgeryBrendan F Judy, Louis A Aliperti, Jarrod D Predina, et al.
Cancer Research|July 20, 2007
The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytesAfrica Wallace, David F LaRosa, Veena Kapoor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive TransferEdmund K Moon, Raghuveer Ranganathan, Evgeniy Eruslanov, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 26, 2024
Red blood cells function as reservoirs of tumor DNAJeffrey C Thompson, Sue Li, Joshua S Jose, et al.
Blood|March 22, 2003
PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosisCunji Gao, Weiyong Sun, Melpo Christofidou-Solomidou, et al.
Pageof 20